VIMTA LABS LTD.-$
P&L
Quarterly Standalone
vs Q3 FY26
Vimta Labs FY26 Revenue Up 19.5% YoY at ₹4,163 Mn
06 May 2026 · 6 May, 4:41 pm
Summary
Vimta Labs Limited announced robust financial results for Q4 and the full fiscal year ended March 31, 2026. The company reported its highest-ever quarterly revenue of Rs. 1,120 Mn in Q4 FY26, contributing to a full-year total income of Rs. 4,163 Mn, representing a 19.5% year-on-year growth. FY26 EBITDA (including other income) increased by 18.0% to Rs. 1,489 Mn with a healthy margin of 35.8%, while Profit After Tax (PAT) from continued operations grew 16.1% year-on-year to Rs. 775 Mn. Managing Director Ms. Harita Vasireddi attributed these strong results to the exceptional performance of the Pharma and Food divisions, sustained demand, operational discipline, and a customer-centric approach, indicating a focus on expanding capabilities and driving sustainable growth.
Key Highlights
- 1
Vimta Labs reported its highest-ever quarterly revenue of Rs. 1,120 Mn in Q4 FY26, marking a 16.6% year-on-year increase.
- 2
For the full financial year FY26, the company achieved a total income of Rs. 4,163 Mn, growing by 19.5% year-on-year compared to FY25.
- 3
EBITDA (including other income) for FY26 rose 18.0% year-on-year to Rs. 1,489 Mn, maintaining a strong EBITDA margin of 35.8%.
- 4
Profit After Tax (PAT) from continued operations for FY26 increased by 16.1% year-on-year to Rs. 775 Mn, with a PAT margin of 18.6%.
- 5
Basic Earnings Per Share (EPS) for FY26 stood at Rs. 17.4, reflecting a 15.9% growth year-on-year.
- 6
The company completed the sale of its Diagnostic and Pathological services business to Thyrocare Technologies on October 11, 2024.
Management Comments
Ms. Harita Vasireddi
We are pleased to close this fiscal year on a strong note, achieving the highest-ever quarterly revenue of Rs. 1,120 Mn, up by 11.5% YoY. On a full-year basis, we crossed an important milestone and achieved a revenue of Rs. 4,163 Mn. These strong results were driven by the exceptional performance of our Pharma, and Food divisions. Sustained demand across sectors for high-quality research and testing services, coupled with the continued trust and confidence demonstrated by our customers, enabled us to deliver a strong EBITDA margin for the year. This performance underscores the strength of our diversified service portfolio, operational discipline, and customer-centric approach. As we move forward, we remain focused on expanding capabilities, investing in technology and talent, and strengthening long-term partnerships to drive sustainable growth and value creation for all stakeholders.
Informational and educational content only. Not investment advice.